A national association of doctors and scientists has demanded that all data pertaining to Covid-19 vaccine trials should be made public to enable scientists and healthcare workers to make informed choices regarding administration of vaccination.
In a statement issued on Sunday, the Progressive Medicos and Scientists Forum said the Clinical Trial (PMSF) Phase 3 data should be evaluated in a transparent manner as and when available for India for both vaccines and the decision to grant Emergency Use Authorization (EUA) may be revisited once the Phase 3 trials are completed.
They demanded that all data pertaining to the vaccine trials should be made public to enable scientists and healthcare workers to make informed choices regarding administration of vaccines for themselves and for their larger communities.
"All healthcare workers should have an option for opting out without any fear, coercion or any other adverse impact on them, including linking vaccination status to air travel restrictions," it said.
The body further demanded that the continuation or eligibility for working as healthcare should not have any precondition of Covid-19 vaccination, as is being done in a few countries.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)